In the case of nivolumab induced SCLE reported by Marano et al, the patient continued nivolumab treatment after the rash recovered, and then it progressed to the anti-melanoma differentiation-associated gene 5 (anti-MDA-5) antibody associated dermatomyositis (28). Here, IFIH1 is linked to dermatomyositis.